Role of sparc in bone remodeling and cancer-related bone metastasis

Journal of Cellular Biochemistry

Volumn 115, Issue 1, 2014, Pages 17-26

  Ribeiro, Nilza ^a,b   Sousa, Susana R ^a,c   Brekken, Rolf A ^d   Monteiro, Fernado J ^a,b  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSTITUTO SUPERIOR DE ENGENHARIA DO PORTO   (Portugal)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BONE METASTASIS; BONE REMODELING; SPARC; TUMORIGENESIS

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 5; METALLOPROTEINASE; OSTEONECTIN; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; THROMBOSPONDIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE METASTASIS; BONE MINERALIZATION; BONE REMODELING; CANCER GROWTH; CARCINOGENESIS; EXTRACELLULAR MATRIX; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; MICROFRACTURE; NONHUMAN; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETON; TISSUE REPAIR; TUMOR MICROENVIRONMENT; TURNOVER TIME;

BONE METASTASIS; BONE REMODELING; SPARC; TUMORIGENESIS;

ANIMALS; BONE NEOPLASMS; BONE REMODELING; HUMANS; NEOPLASMS; OSTEONECTIN;

EID: 84887856025     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24649     Document Type: Article

References (88)

1. Alford AI, Hankenson KD,. 2006. Matricellular proteins: Extracellular modulators of bone development, remodeling, and regeneration. Bone 38: 749-757.
2. Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, Pitossi FJ, Chuluyan HE, Podhajcer OL,. 2005. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 65: 5123-5132.
3. Anselme K, Bigerelle M,. 2005. Topography effects of pure titanium substrates on human osteoblast long-term adhesion. Acta Biomater 1: 211-222.
4. Arnold SA, Brekken RA,. 2009. SPARC: A matricellular regulator of tumorigenesis. J Cell Commun Signal 3: 255-273.
5. Boskey AL, Moore DJ, Amling M, Canalis E, Delany AM,. 2003. Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res 18: 1005-1011.
6. Boskey AL, Doty SB, Kudryashov V, Mayer-Kuckuk P, Roy R, Binderman I,. 2008. Modulation of extracellular matrix protein phosphorylation alters mineralization in differentiating chick limb-bud mesenchymal cell micromass cultures. Bone 42: 1061-1071.
7. Bradshaw AD,. 2012. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell B 44: 480-488.
8. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, Sage EH,. 2003. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 120: 949-955.
9. Brekken RA, Sage EH,. 2000. SPARC, a matricellular protein: At the crossroads of cell matrix. Matrix Biol 19: 569-580.
10. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH,. 2003. Enhanced growth of tumors in SPARC null mice is associated with changes the ECM. J Clin Invest 111: 487-495.
11. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ,. 2002. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21: 7077-7091.
12. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA,. 2000. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83.
13. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT,. 2008. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′ deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 98: 1810-1819.
14. Chen NY, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH,. 2007. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67: 6544-6548.
15. Chlenski A, Liu SQ, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang QW, Salwen HR, Farrer R, Bray J, Cohn SL,. 2002. SPARC is a key Schwannian derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62: 7357-7363.
16. Chlenski A, Liu SQ, Baker LJ, Yang QW, Tian YF, Salwen HR, Cohn SL,. 2004. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res 64: 7420-7425.
17. Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, Yang QW, Tian YF, Salwen HR, Cohn SL,. 2010. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer 9.
18. De S, Chen JH, Narizhneva NV, Heston W, Brainard J, Sage EH, Byzova TV,. 2003. Molecular pathway for cancer metastasis to bone. J Biol Chem 278: 39044-39050.
19. DeRosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Siefert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G,. 2012. Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis 15: 150-156.
20. Doi Y, Okuda R, Takezawa Y, Shibata S, Moriwaki Y, Wakamatsu N, Shimizu N, Moriyama K, Shimokawa H,. 1989. Osteonectin inhibiting denovo formation of apatite in the presence of collagen. Calcif Tissue Int 44: 200-208.
21. Donahue HJ,. 2004. Summary-Bone metastasis. J Musculoskelet Neuronal Interact 4: 381-382.
22. Fauci AS, Longo DL,. 2008. Bone and mineral metabolism in health and disease. In:, Fauci AS, Longo DL, editors. Harrison's principles of internal medicine. McGraw-Hill, United States of America; pp 2365-2377.
23. Framson PE, Sage EH,. 2004. SPARC and tumor growth: Where the seed meets the soil ? J Cell Biochem 92: 679-690.
24. Funk SE, Sage EH,. 1991. The Ca 2+ binding glycoprotein SPARC modulates cell-cycle progression in bovine endothelial-cells. Proc Natl Acad Sci USA 88: 2648-2652.
25. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J,. 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803.
26. Graham JD, Balleine RL, Milliken JS, Bilous AM, Clarke CL,. 1997. Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. Eur J Cancer 33: 1654-1660.
27. Haber CL, Gottifredi V, Llera AS, Salvatierra E, Prada F, Alonso L, Helene SE, Podhacjer OL,. 2008. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated (vol 122, pg 1465, 2008). Int J Cancer 123: 245-245.
28. Hohenester E, Maurer P, Timpl R,. 1997. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. EMBO J 16: 3778-3786.
29. Hohenester E, Sasaki T, Giudici C, Farndale RW, Bachinger HP,. 2008. Structural basis of sequence-specific collagen recognition by SPARC. Proc Natl Acad Sci USA 105: 18273-18277.
30. Inoue M, Senju S, Hirata S, Ikuta Y, Hayashida Y, Irie A, Harao M, Imai K, Tomita Y, Tsunoda T, Furukawa Y, Ito T, Nakamura Y, Baba H, Nishimura Y,. 2010. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer 127: 1393-1403.
31. Jacob K, Webber M, Benayahu D, Kleinman HK,. 1999. Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 59: 4453-4457.
32. Kapinas K, Lowther KM, Kessler CB, Tilbury K, Lieberman JR, Tirnauer JS, Campagnola P, Delany AM,. 2012. Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol 31: 299-307.
33. Kato Y, Frankenne F, Noel A, Sakai N, Nagashima Y, Koshika S, Miyazaki K, Foidart JM,. 2000. High production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines. Pathol Oncol Res 6: 24-26.
34. Kelly KA, Waterman P, Weissleder R,. 2006. In vivo imaging of molecularly targeted phage. Neoplasia 8: 1011-1018.
35. Kelm RJ, Mann KG,. 1991. The collagen binding-specificty of bone and platelet osteonectin is related to differences in glycosylation. J Biol Chem 266: 9632-9639.
36. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang SL, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK,. 2005. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65: 7370-7377.
37. Kupprion C, Motamed K, Sage EH,. 1998. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273: 29635-29640.
38. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vjiver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JGM, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF, Breast Cancer Linkage Consortium. 2005. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11: 5175-5180.
39. Lane TF, Sage EH,. 1994. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 8: 163-173.
40. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816.
41. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL,. 1997. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3: 171-176.
42. Liao S, Ngiam M, Chan CK, Ramakrishna S,. 2009. Fabrication of nanohydroxyapatite/collagen/osteonectin composites for bone graft applications. Biomed Mater 4 (2): 025019.
43. Liotta LA, Kohn EC,. 2001. The microenvironment of the tumour-host interface. Nature 411: 375-379.
44. Lopez MV, Blanco P, Viale DL, Cafferata EG, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL,. 2006. Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Mol Cancer Ther 5: 2503-2511.
45. Manuel CM, Foster M, Monteiro FJ, Ferraz MP, Doremus RH, Bizios R,. 2003. Preparation and characterization of calcium phosphate nanoparticles. In: 16th International Symposium on Ceramics in Medicine., Barbosa MA, Monteiro FJ, Correia R, Leon B, editors. Porto, Portugal: Trans Tech Publications Ltd. pp 903-906.
46. McCabe NP, Kerr BA, Madajka M, Vasanji A, Byzova TV,. 2011. Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer. Neoplasia 13: 31-39.
47. McKnight DAC, Sosnoski DM, Koblinski JE, Gay CV,. 2006. Roles of osteonectin in the migration of breast cancer cells into bone. J Cell Biochem 97: 288-302.
48. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, Palacios J, Cano A,. 2006. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66: 9543-9556.
49. Nie J, Sage EH,. 2009. SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J Biol Chem 284: 1279-1290.
50. Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF,. 2009. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol 175: 1255-1269.
51. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C,. 1995. Neoplastic progression of human colorectal-cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 64: 70-75.
52. Prada F, Benedetti LG, Bravo AI, Alvarez MJ, Carbone C, Podhajcer OL,. 2007. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J Invest Dermatol 127: 2618-2628.
53. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD,. 2007. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 282: 22062-22071.
54. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, Sabatie E, Cano A, de Herreros GA, Ballotti R, Tartare-Deckert S,. 2006. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 66: 7516-7523.
55. Romberg RW, Werness PG, Lollar P, Riggs BL, Mann KG,. 1985. Isolation and characterization of native adult osteonectin. J Biol Chem 260: 2728-2736.
56. Romberg RW, Werness PG, Riggs BL, Mann KG,. 1986. Inhibition of hydroxyapatite crystal-growth by bone-sppecific and other calcium-binding proteins. Biochemistry 25: 1176-1180.
57. Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA,. 2003. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 278: 37849-37857.
58. Said N, Motamed K,. 2005. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167: 1739-1752.
59. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K,. 2007. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 5: 1015-1030.
60. Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, Colombo MP,. 2003. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 198: 1475-1485.
61. Sarvestani AS, He X, Jabbari E,. 2008. Osteonectin-derived peptide increases the modulus of a bone-mimetic nanocomposite. Eur Biophys J 37: 229-234.
62. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH, Goggins M,. 2003. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22: 5021-5030.
63. Schultz C, Lemke N, Ge SG, Golembieski WA, Rempel SA,. 2002. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62: 6270-6277.
64. Shi Q, Bao SD, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN,. 2004. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279: 52200-52209.
65. Shi Q, Bao S, Song L, Bigner DD, Hjelmeland AB, Rich JN,. 2007. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26: 4084-4094.
66. Smit DJ, Gardiner BB, Sturm RA,. 2007. Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 121: 2653-2660.
67. Sosa MS, Girotti MR, Salvatierra E, Prada F, de Olmo JAL, Gallango SJ, Albar JP, Podhajcer OL, Llera AS,. 2007. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 7: 4123-4134.
68. Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K, Gazdar AF,. 2005. Aberrant methylation of SPARC in human lung cancers. Br J Cancer 92: 942-948.
69. Sweetwyne MT, Brekken RA, Workman G, Bradshaw AD, Carbon J, Siadak AW, Murri C, Sage EH,. 2004. Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem 52: 723-733.
70. Taghizadeh F, Tang MJ, Tai IT,. 2007. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther 6: 309-317.
71. Tai IT, Tang MJ,. 2008. SPARC in cancer biology: Its role in cancer progression and potential for therapy. Drug Resist Updat 11: 231-246.
72. Tai IT, Dai M, Owen DA, Chen LB,. 2005. Genome-wide expression analysis of therapy resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 115: 1492-1502.
73. Tang MJ, Tai IT,. 2007. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 282: 34457-34467.
74. Tartare-Deckert S, Chavey C, Monthouel MN, Gautier N, Van Obberghen E,. 2001. The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity. J Biol Chem 276: 22231-22237.
75. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR,. 1981. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26: 99-105.
76. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL,. 2000. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6: 1140-1149.
77. Tremble PM, Lane TF, Sage EH, Werb Z,. 1993. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblats through a novel extracellular matrix-dependent pathway. J Cell Biol 121: 1433-1444.
78. Vajkoczy P, Menger MD, Goldbrunner R, Ge SG, Fong TAT, Vollmar B, Schilling L, Ullrich A, Hirth KP, Tonn JC, Schmiedek P, Rempel SA,. 2000. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int J Cancer 87: 261-268.
79. Von Hoff DD, Borad M, Ramanathan RK, Smith LS, Drengler RL, Wood TE, Laheru D, Hedalgo M,. 2008. Promising clinical activity of a NAB pacitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer. In: Proceedings of the 99th Annual Meeting, Am. Assoc. Cancer Res, San Diego, CA.
80. Walsh WR, Walton M, Bruce W, Yu Y, Gillies RM, Svehla M,. 2003. PART II-Structure and function of bone and cartilage. In:, An YH, Martin KL, editors. Handbook of histology methods for bone and cartilage. Totowa, NJ: Humana Press Inc. 35-73.
81. Wang H, Fertala A, Ratner BD, Sage EH, Jiang SY,. 2005. Identifying the SPARC binding sites on collagen I and procollagen I by atomic force microscopy. Anal Chem 77: 6765-6771.
82. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM,. 2001. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978.
83. Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shent SS, Whittaker CA, Crowley D, Hynes RO,. 2007. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 104: 12784-12789.
84. Wong SY, Crowley D, Bronson RT, Hynes RO,. 2008. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis 25: 109-118.
85. Yan Q, Sage EH,. 1999. SPARC, a matricellular glycoprotein with important biological functions. In: 50th Annual Meeting of the Histochemical-Society. Bethesda, MD: Histochemical Soc Inc. pp 1495-1505.
86. Yang EN, Kang HJ, Koh KH, Rhee H, Kim NK, Kim HG,. 2007. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121: 567-575.
87. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC,. 2001. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609-622.
88. Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, Wang J, Zhou Y, Yu L, Fang B, Swisher SG,. 2010. KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther 9: 507-513.